Nonpharmacological Interventions for the Treatment of Cardiometabolic Risk Factors in People With Schizophrenia—A Systematic Review
Background: People suffering from schizophrenia are notably vulnerable to cardiometabolic risk factors (CMRF), such as obesity, high blood pressure, hyperglycemia and insulin resistance, high serum triglycerides, and low serum high-density lipoprotein (HDL), which are related to increased mortality...
Main Authors: | Ewa Tumiel, Adam Wichniak, Marek Jarema, Michał Lew-Starowicz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-08-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2019.00566/full |
Similar Items
-
Exploring Lead loci shared between schizophrenia and Cardiometabolic traits
by: Qian He, et al.
Published: (2022-08-01) -
Cardiometabolic outcomes among schizophrenia patients using antipsychotics: the impact of high weight gain risk vs low weight gain risk treatment
by: Rezaul Khandker, et al.
Published: (2022-02-01) -
Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study
by: Silvana Galderisi, et al.
Published: (2021-01-01) -
Association of clinical symptoms and cardiometabolic dysregulations in patients with schizophrenia spectrum disorders
by: Chenxu Zhao, et al.
Published: (2024-01-01) -
Schizophrenia and cardiometabolic abnormalities: A Mendelian randomization study
by: Noushin Saadullah Khani, et al.
Published: (2023-04-01)